TR200200165T2 - Substituted imidazothiazoles as antidepressants - Google Patents
Substituted imidazothiazoles as antidepressantsInfo
- Publication number
- TR200200165T2 TR200200165T2 TR2002/00165T TR200200165T TR200200165T2 TR 200200165 T2 TR200200165 T2 TR 200200165T2 TR 2002/00165 T TR2002/00165 T TR 2002/00165T TR 200200165 T TR200200165 T TR 200200165T TR 200200165 T2 TR200200165 T2 TR 200200165T2
- Authority
- TR
- Turkey
- Prior art keywords
- disorders
- treatment
- cerebral ischemia
- eating
- neurological
- Prior art date
Links
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 title 1
- 239000000935 antidepressant agent Substances 0.000 title 1
- 229940005513 antidepressants Drugs 0.000 title 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 2
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000034158 bleeding Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 235000005686 eating Nutrition 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 230000008447 perception Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Formül I e sahip bilesikler ve bunlarin farmasötik açidan kabul edilebilir tuzlari (burada: A,S veya O dur; R1, H, halo, bir C1-3alkil grubu veya bir C1-3 alkiltio grubudur;R2, H ve flordur; ve R3, metil, etil veya izopropildir),depresyon, asiri endise, psikozlar (örnegin sizofreni), yavas gelisen diskinezi,asiri sismanlik, ilaç bagimliligi, ilaç suistimali, algilama bozukluklari,Alzheimer hastaligi, beyinsel iskemi, obsesif-kompalsif davranis, panik nöbetleri, sosyal fobiler, bulimiya,anoreksiya,aburcubur yeme içme gibi yeme bozukluklari, insüline bagimli olmayan sekerli diyabet, hiperglisemi, hiperlipidemi ve stresin tedavisinde ve nöbetler,epilepsi gibi nörolojik bozukluklar ve/veya felç, beyin travmasi, beyinsel iskemi, bas yaralanmalari ve kanamalari gibi nörolojik hasar olusan durumlarin tedavisi ve/veya önlemesi için yararlidirlar.Compounds of Formula I and their pharmaceutically acceptable salts (wherein: A is S or O; R1 is H, halo, a C1-3alkyl group or a C1-3 alkylthio group; R2 is H and fluorine; and R3 is methyl, ethyl or isopropyl), depression, extreme anxiety, psychosis (eg schizophrenia), slowly developing dyskinesia, excessive dysfunction, drug addiction, drug abuse, perception disorders, Alzheimer's disease, cerebral ischemia, obsessive-compulsive behavior, panic attacks, social phobias in the treatment of eating disorders such as bulimia, anorexia, eating junk food, non-insulin dependent diabetes mellitus, hyperglycemia, hyperlipidemia and stress, and neurological disorders such as seizures, epilepsy, and / or neurological damage such as stroke, brain trauma, cerebral ischemia, headache and bleeding. they are useful for the treatment and / or prevention of conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9911881.2A GB9911881D0 (en) | 1999-05-21 | 1999-05-21 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200165T2 true TR200200165T2 (en) | 2002-05-21 |
Family
ID=10853927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00165T TR200200165T2 (en) | 1999-05-21 | 2000-05-11 | Substituted imidazothiazoles as antidepressants |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1187836A1 (en) |
| JP (1) | JP2003500409A (en) |
| KR (1) | KR20020033625A (en) |
| CN (1) | CN1361782A (en) |
| AU (1) | AU4565200A (en) |
| BG (1) | BG106228A (en) |
| BR (1) | BR0010828A (en) |
| CA (1) | CA2374915A1 (en) |
| CZ (1) | CZ20014172A3 (en) |
| GB (1) | GB9911881D0 (en) |
| HU (1) | HUP0201543A2 (en) |
| IL (1) | IL146541A0 (en) |
| MX (1) | MXPA01011896A (en) |
| NO (1) | NO20015668L (en) |
| PL (1) | PL352288A1 (en) |
| SK (1) | SK16842001A3 (en) |
| TR (1) | TR200200165T2 (en) |
| WO (1) | WO2000071548A1 (en) |
| ZA (1) | ZA200110021B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0005789D0 (en) * | 2000-03-11 | 2000-05-03 | Knoll Ag | Therapeutic agents |
| GB0023610D0 (en) * | 2000-09-27 | 2000-11-08 | Knoll Ag | Therapeutic agents |
| CN100396667C (en) * | 2006-02-20 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | A group of five-membered unsaturated heterocyclic compounds with the activity of up-regulating the expression of bone morphogenic protein BMP-2 |
| US8758373B2 (en) | 2008-02-18 | 2014-06-24 | Covidien Lp | Means and method for reversibly connecting a patch to a patch deployment device |
| US9044235B2 (en) | 2008-02-18 | 2015-06-02 | Covidien Lp | Magnetic clip for implant deployment device |
| US9034002B2 (en) | 2008-02-18 | 2015-05-19 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US8317808B2 (en) | 2008-02-18 | 2012-11-27 | Covidien Lp | Device and method for rolling and inserting a prosthetic patch into a body cavity |
| US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
| AU2009215269B2 (en) | 2008-02-18 | 2013-01-31 | Covidien Lp | A device and method for deploying and attaching a patch to a biological tissue |
| US9398944B2 (en) | 2008-02-18 | 2016-07-26 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US9301826B2 (en) | 2008-02-18 | 2016-04-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| US9393002B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
| US8808314B2 (en) | 2008-02-18 | 2014-08-19 | Covidien Lp | Device and method for deploying and attaching an implant to a biological tissue |
| US9833240B2 (en) | 2008-02-18 | 2017-12-05 | Covidien Lp | Lock bar spring and clip for implant deployment device |
| EP2792307B1 (en) | 2008-10-20 | 2017-10-04 | Covidien LP | A device for attaching a patch to a biological tissue |
| US8906045B2 (en) | 2009-08-17 | 2014-12-09 | Covidien Lp | Articulating patch deployment device and method of use |
| EP2467066B1 (en) | 2009-08-17 | 2019-03-27 | Covidien LP | Means for reversibly connecting an implant to a deployment device |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160768A (en) * | 1976-12-29 | 1979-07-10 | Diamond Shamrock Corporation | Anti-inflammatory 3-benzofuranyl imidazothiazole |
| GB9513467D0 (en) * | 1995-07-01 | 1995-09-06 | Knoll Ag | Therapeutic agents |
| GB9705428D0 (en) * | 1997-03-15 | 1997-04-30 | Knoll Ag | Therapeutic agents |
-
1999
- 1999-05-21 GB GBGB9911881.2A patent/GB9911881D0/en not_active Ceased
-
2000
- 2000-05-11 WO PCT/EP2000/004278 patent/WO2000071548A1/en not_active Application Discontinuation
- 2000-05-11 MX MXPA01011896A patent/MXPA01011896A/en unknown
- 2000-05-11 EP EP00927197A patent/EP1187836A1/en not_active Withdrawn
- 2000-05-11 BR BR0010828-6A patent/BR0010828A/en not_active IP Right Cessation
- 2000-05-11 PL PL00352288A patent/PL352288A1/en not_active Application Discontinuation
- 2000-05-11 AU AU45652/00A patent/AU4565200A/en not_active Abandoned
- 2000-05-11 JP JP2000619804A patent/JP2003500409A/en not_active Withdrawn
- 2000-05-11 CZ CZ20014172A patent/CZ20014172A3/en unknown
- 2000-05-11 IL IL14654100A patent/IL146541A0/en unknown
- 2000-05-11 HU HU0201543A patent/HUP0201543A2/en unknown
- 2000-05-11 CN CN00810593A patent/CN1361782A/en active Pending
- 2000-05-11 TR TR2002/00165T patent/TR200200165T2/en unknown
- 2000-05-11 KR KR1020017014885A patent/KR20020033625A/en not_active Withdrawn
- 2000-05-11 SK SK1684-2001A patent/SK16842001A3/en unknown
- 2000-05-11 CA CA002374915A patent/CA2374915A1/en not_active Abandoned
-
2001
- 2001-11-20 NO NO20015668A patent/NO20015668L/en not_active Application Discontinuation
- 2001-12-05 ZA ZA200110021A patent/ZA200110021B/en unknown
- 2001-12-17 BG BG106228A patent/BG106228A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK16842001A3 (en) | 2002-04-04 |
| NO20015668D0 (en) | 2001-11-20 |
| CN1361782A (en) | 2002-07-31 |
| KR20020033625A (en) | 2002-05-07 |
| CA2374915A1 (en) | 2000-11-30 |
| CZ20014172A3 (en) | 2002-04-17 |
| HUP0201543A2 (en) | 2002-08-28 |
| BG106228A (en) | 2002-08-30 |
| AU4565200A (en) | 2000-12-12 |
| NO20015668L (en) | 2002-01-21 |
| PL352288A1 (en) | 2003-08-11 |
| WO2000071548A1 (en) | 2000-11-30 |
| JP2003500409A (en) | 2003-01-07 |
| GB9911881D0 (en) | 1999-07-21 |
| BR0010828A (en) | 2002-06-11 |
| EP1187836A1 (en) | 2002-03-20 |
| ZA200110021B (en) | 2003-05-28 |
| MXPA01011896A (en) | 2004-03-19 |
| IL146541A0 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200165T2 (en) | Substituted imidazothiazoles as antidepressants | |
| TR200200164T2 (en) | Thiazolo derivatives and pharmaceutical reactions containing them | |
| CA2401033A1 (en) | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | |
| BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
| NZ507763A (en) | N-substituted aminotetralin sulphonamide derivatives useful as ligands for the neuropeptide Y Y5 receptor used in the treatment of obesity and other disorders | |
| DE69426331D1 (en) | MEDICINE FOR NERVOUS DISEASES | |
| TW200738696A (en) | Isoxazolines for controlling invertebrate pests | |
| EP0945439A4 (en) | NEW AMINOPYRAZOLE DERIVATIVES | |
| NO954542L (en) | 1-Arylcycloalkyl sulfides, sulfoxides and sulfones for the treatment of depression, anxiety and Parkinson's disease | |
| IL158828A0 (en) | Novel heteroaryl derivatives, their preparation and use | |
| BR0209342A (en) | Azaheterocyclylmethyl antidepressants derived from 2,3 dihydro-1,4-dioxino [2,3-f] quinoxaline; method of treatment using such compounds; process to prepare them | |
| TR199701756T1 (en) | Concentrated thiazole derivatives with 5-HT affinity receptors. | |
| FI956230A0 (en) | beta-aminovinyl ketones, method of preparation and their use in the preparation of beta-diketones | |
| MXPA03000429A (en) | Novel aniline derivatives. | |
| TW200505892A (en) | Substituted 3-(benzoylureido)thiophene derivatives, processes for preparing them and their use | |
| BR9714237A (en) | Compounds, use of a compound, processes for treating depression, anxiety, psychosis, tardive dyskinesia, parkinson's disease, obesity, hypertension, tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive illness, alzheimer's disease, senile dementia , obsessive compulsive behavior, panic attacks, social phobias, diseases and food anorexia, cardiovascular and cerebrovascular diseases, diabetes mellitus not dependent on insulin, hyperglycemia, constipation, arrhythmia, diseases of the neuroendocrine system, tension and spasticity in humans and for preparation of compounds, and pharmaceutical composition. | |
| CA2155796A1 (en) | 2,3-dihydro-1h-isoindole derivatives, a process for their preparation and their use as serotonin reuptake inhibitors | |
| ES2094048T3 (en) | N-ACILPIRROLIDINAS AND MEDICINES FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO CHOLECYSTOCININ AND GASTRINE. | |
| CO5690542A2 (en) | METHOD FOR THE PRODUCTION OF ACIL-FENIL-UREA DERIVATIVES REPLACED BY ANIMO-CARBON AND THE USE OF THE SAME | |
| WO2004062361A3 (en) | Spiro compounds | |
| CA2151503A1 (en) | 2,3-Dihydrobenzofuran Derivatives | |
| WO2005002573A3 (en) | Methods for using modulators of proline-rich tyrosine kinase 2 | |
| AU2001251662A1 (en) | Benzoxazines for use in the treatment of parkinson's disease | |
| MXPA04005550A (en) | Substituted cyclohexane derivatives. | |
| KR950011399A (en) | Disinfectant Indanylamine Compounds, Derivatives thereof, and Methods for Preparing the Same |